Real-World Impact of a National Funding-Driven Transition Between Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes
Authors' conclusion
Funding-driven AID transitions can be safely implemented with structured education and follow-up.
Study context
- Population
- Children/adolescents with T1D using Medtronic automated insulin delivery (AID), transitioned after New Zealand PHARMAC funding change; mean age 11.6 ± 3.0 years79 with complete 6-month data
- Participants
- 98 participants
- Exposure
- Transition from Medtronic AID to funded AID systems
- Tandem Control-IQn = 66
- YpsoPump with CamAPS FXn = 11
- Outcome
- Glycemic outcomes
- Follow-up
- 6 months post-transition
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
HbA1c
Mean HbA1c decrease
0.24%
Mean HbA1c before vs after transition
7.14 ± 0.79% to 6.87 ± 0.86%
P = 0.0012
Observational data: associations, not effects.
Safety
- Episodes of DKA or level 3 hypoglycemia
- 0
Original publication
Real-World Impact of a National Funding-Driven Transition Between Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes. Diabetes Technol Ther. Published 2 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →